End-to-End Support Across the Entire Drug Lifecycle

At Axleres Biosciences, we provide full-spectrum scientific and project execution services that support your program from early discovery through commercial readiness — across New Chemical Entities (NCEs), New Biological Entities (NBEs), peptides, oligonucleotides, mRNA therapeutics, and other novel modalities. 

With our asset-light, partner-powered model, we bring you deep domain expertise, pre-qualified partner networks, agile project leadership, and seamless integration across functional and geographic boundaries. 

• Access to high-throughput screening (HTS), fragment-based drug discovery (FBDD), structure-based design (SBDD), and AI-driven virtual screening 
• Compound library sourcing and curation 
• Assay development and validation across biochemical, biophysical, and cell-based systems 

• Medicinal chemistry design and SAR exploration for NCEs, macrocycles, peptidomimetics, and hybrid modalities 
• Iterative optimization for potency, selectivity, ADME, and developability 
• Scaffold hopping, bioisosteric replacement, and metabolite-directed design 

• In vitro/in vivo efficacy models 
• In vitro ADME profiling (solubility, permeability, metabolic stability, CYP inhibition, transporter assays) 
• Early PK/PD and tolerability studies in relevant models 

• Biomarker discovery and validation 
• Pathway deconvolution and pharmacological profiling 
• Integration of in vitro/in vivo correlation to guide decision-making 

• Full target product profile (TPP) alignment 
• GO/NO-GO criteria governance 
• Portfolio triaging and risk assessment support